Adjuvant IO Strategies in Endometrial Cancer: RAINBO and GY020
A brief review of clinical trial data from RAINBO and GY020, which tested adjuvant immunotherapy following radiation in patients with endometrial cancer.
EP: 1.Patient Case: A 64-Year-Old Woman With Recurrent Endometrial Cancer
EP: 2.Endometrial Cancer: Factors in Selecting First- and Second-Line Therapy
EP: 3.Immune Checkpoint Inhibitors in Recurrent Endometrial Cancer: Clinical Trial Data
EP: 4.Recurrent Endometrial Cancer: An Evolving Treatment Landscape
EP: 5.Combination IO Strategies in Advanced Endometrial Cancer: RUBY and GY018
EP: 6.Single-Agent IO Therapy in Advanced Endometrial Cancer: PHAEDRA and DOMENICA
EP: 7.Adjuvant IO Strategies in Endometrial Cancer: RAINBO and GY020
EP: 8.Antibody Drug Conjugate Data in Endometrial Cancer: TROPiCS-03
EP: 9.Future Directions in the Management of Endometrial Cancer
Transcript:
Ritu Salani, MD, MBA: The next trial progress that I want to highlight is the RAINBO MMRd-GREEN trial, which is a phase 3 trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk mismatch repair deficient endometrial cancer. This is an open-label randomized phase 3 trial that's looking at durvalumab once every 4 weeks combined with radiotherapy or radiotherapy alone, for early-stage high-risk patients. Once again, [we are] moving immunotherapy even earlier in the landscape of the treatment. It is going to focus on this mismatch repair deficient endometrial cancers after hysterectomy and staging surgery. Using this molecular classification, we're targeting that high-risk group, so this study will also help inform practice. GY020 is a similar study looking at pembrolizumab in this setting. We're really looking forward to these results to see how this will continue to help inform practice.
Transcript edited for clarity.
Roundtable Roundup: Treatment for Metastatic pMMR Endometrial Cancer
July 23rd 2024In separate, live virtual events, Michael J. Birrer, MD, PhD, and Jubilee Brown, MD, surveyed participants on the treatment of a postmenopausal woman with stage IVA endometrial cancer after first-line chemotherapy.
Read More
Durvalumab Plus Chemotherapy Wins FDA Approval in dMMR Endometrial Cancer
June 14th 2024The FDA has approved a treatment regimen combining durvalumab with carboplatin and paclitaxel, followed by durvalumab monotherapy, for adults with primary advanced or recurrent endometrial cancer that is deficient in mismatch repair.
Read More
Birrer Assesses Tolerability Factors in Use of Lenvatinib/Pembrolizumab for Endometrial Cancer
June 11th 2024During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion focusing on dosing and tolerability issues in treating patients with advanced endometrial cancer with lenvatinib plus pembrolizumab.
Read More
